MRNA · Moderna, Inc.
$49.202026-05-17Sector: Healthcare; Industry: Biotechnology; Sub-Industry: Biotechnology
Intrinsic Value Range Comparison · Mulya.ai
Leases factoredBull
$0
-32583.8% vs market
Base · active
$0
-31493.2% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($-735 · $-15982) Analysts Range ($17 · $63) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2021.Q4 | $17.7B | — | 73.6% | 8.2% | $12.0B | $3.1B | $15.1B | 9.5% | — | 679.7% | $1.8B | $31.13 | — |
| 2022.Q4 | $18.9B | 6.4% | 49.0% | 12.7% | $8.1B | −$2.2B | $5.9B | 10.1% | — | 163.8% | $8.1B | $21.33 | — |
| 2023.Q4 | $6.8B | -63.7% | -61.9% | 0.0% | −$5.1B | −$905MM | −$6.0B | 9.7% | — | -72.6% | $5.9B | $-12.03 | — |
| 2024.Q4 | $3.2B | -53.3% | -123.3% | 1.3% | −$3.9B | $321MM | −$3.6B | 10.3% | — | -75.4% | $4.5B | $-9.08 | — |
| 2025.Q4 | $1.9B | -39.3% | -155.2% | 0.0% | −$3.1B | −$283MM | −$3.4B | 10.4% | — | -68.4% | $4.5B | $-7.20 | — |
| italics below = DCF projection · 10yr Rev CAGR: 21.4% |
| 2026.Q4 | $2.1B | +6.8% | -8126.0% | 2.0% | −$165.3B | −$246MM | −$165.6B | 8.9% | −$152.0B | -3556.6% | $4.8B | $-1.37 | — |
| 2027.Q4 | $2.5B | +20.5% | -8126.0% | 4.0% | −$195.2B | −$846MM | −$196.0B | 8.9% | −$165.2B | -3757.9% | $5.6B | $-1.62 | — |
| 2028.Q4 | $3.2B | +26.0% | -8126.0% | 6.0% | −$240.8B | −$1.4B | −$242.1B | 8.9% | −$187.4B | -3813.6% | $7.0B | $-2.00 | — |
| 2029.Q4 | $5.0B | +59.0% | -8126.0% | 8.0% | −$374.7B | −$1.0B | −$375.7B | 8.8% | −$267.2B | -4980.3% | $8.0B | $-3.11 | — |
| 2030.Q4 | $6.6B | +32.5% | -8126.0% | 10.0% | −$485.8B | −$788MM | −$486.6B | 8.8% | −$318.0B | -5762.2% | $8.8B | $-4.03 | — |
|
| Term. Yr+ | $14.0B | 4.1% | -8082.3% | 20.0% | −$906.8B | $432.3B | −$474.5B | 8.6% | −$4541.3B | 8.6% | — | — | — |
Active scenario IV: $0 (-31493.2% vs market)